Cardiovascular Diseases, Coronary Artery Disease, Coronary Disease, Coronary Syndrome, SCAD
Conditions
Brief summary
Within a CAD patient cohort there is a wide variability of clinical manifestation and severity of coronary disease. Distinct determinants that would explain the variety of CAD phenotypes with differing prognosis are yet undiscovered. Aim of this study is to find genetic variants, biomarkers, and clinical cardiovascular risk factors that relate to specific coronary artery disease phenotypes and related pathologies in a patient population.
Detailed description
Atherosclerotic Coronary Artery Disease (CAD) is one of the leading causes of death in industrialized countries and accounts for a high lifetime prevalence. Within a CAD patient cohort there is a broad inter-individual difference with regard to clinical manifestation and severity of disease, e.g. stable angina vs. acute coronary syndrome, calcified vs. thrombotic coronary lesions or one vessel vs. complex three vessel disease or left main stenosis. Thus, depending on the CAD phenotype there is a broad difference in CAD patients' prognosis. Similarly, other non-atherosclerotic coronary pathologies such as Spontaneous Coronary Dissection (SCAD) are related with devastating illness in mainly young patients. For these patients there is an unmet need in the knowledge of epidemiology, presentation, current management and outcome. Aim of this study is to discover genetic variants, biomarkers, and clinical cardiovascular risk factors that relate to specific CAD (and related coronary pathologies) phenotypes in a national patient population. This may allow an improvement of individualized risk stratification and contribute to discover pathways in the pathogenesis and open the avenue for potential therapeutic targets.
Interventions
None listed
Sponsors
University of Hamburg-Eppendorf
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Individuals with a minimum age of 18 years * Any patient with an available complete coronary angiography * Ability to provide written informed consent in accordance with Good Epidemiological Practice and local legislation
Exclusion criteria
* Physical or psychological incapability to take part in the study * Known anaemia (Hemoglobin \< 7.5 g/dl)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with non-fatal or fatal major adverse cardiovascular events (MACE) | Through study completion, an average of 5 years | MACE as a composite endpoint consists of * occurrence of non-fatal and fatal myocardial infarction * occurrence of non-fatal and fatal stroke * need for coronary revascularization (percutaneous coronary intervention or coronary bypass graft operation) Endpoints will be recorded by telephone interview during census follow up. All endpoint information will be validated by official medical records. |
| All-cause mortality | Through study completion, an average of 5 years | Information from the population register will be used to assess all-cause mortality. |
Countries
Germany
Outcome results
None listed